| Accession Number | 0001193125-26-414688 |
|---|---|
| Form Type | 4 |
| Filing Date | Oct 5, 2026 |
| Document | View SEC Filing |
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
President, Oncology | Common Stock | โ | Oct 2, 2026 | Exercise/Conversion | 8,333 | $21.63 | $180,242.79 | 12,279 | Direct | โ | View Details | |
President, Oncology | Common Stock | โ | Oct 2, 2026 | Sale | 1,100 | $114.52 | $125,972.55 | 11,179 | Direct | โ | View Details | |
President, Oncology | Common Stock | โ | Oct 2, 2026 | Sale | 2,086 | $115.73 | $241,412.36 | 9,093 | Direct | โ | View Details | |
President, Oncology | Common Stock | โ | Oct 2, 2026 | Sale | 5,147 | $116.58 | $600,062.99 | 3,946 | Direct | โ | View Details | |
President, Oncology | Stock option (right to buy) | Derivative | Oct 2, 2026 | Exercise/Conversion | 8,333 | $0.00 | $0.00 | 133,334 | Direct | โ | View Details |